SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
74.01
-0.74 (-0.99%)
As of 10:46AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close74.75
Open74.75
Bid74.62 x 2200
Ask74.65 x 800
Day's Range73.94 - 74.76
52 Week Range47.75 - 84.37
Volume85,078
Avg. Volume816,604
Market Cap11.752B
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateOct 25, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est87.45
Trade prices are not sourced from all markets
  • How Acadia Pharmaceuticals Is Positioned Financially
    Market Realist1 hour ago

    How Acadia Pharmaceuticals Is Positioned Financially

    Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.

  • Analysts Mostly Positive on Acadia Pharmaceuticals
    Market Realist3 hours ago

    Analysts Mostly Positive on Acadia Pharmaceuticals

    Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • A Financial Overview of Ionis Pharmaceuticals in October
    Market Realist8 days ago

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.

  • Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress
    Business Wire9 days ago

    Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress

    Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (SGEN) announced today that updated clinical data from the innovaTV 201 Phase II study evaluating tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer will be presented as a poster at the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany from October 19 to 23, 2018. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen, which is expressed on a broad range of solid tumors. “We look forward to presenting an update on the expanded cervical cancer cohort data showing that tisotumab vedotin continues to demonstrate tolerability and clinical activity in heavily pretreated patients with cervical cancer.

  • Cara Therapeutics: Performance and Estimates for Q3
    Market Realist12 days ago

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.

  • What Seattle Genetics’ Valuation Trend Indicates
    Market Realist12 days ago

    What Seattle Genetics’ Valuation Trend Indicates

    In October, of the 13 analysts covering Seattle Genetics (SGEN), eight analysts gave the stock a “buy” or a higher rating, while five analysts gave the stock a “hold” rating. The mean rating for Seattle Genetics stock is 2.15 with a target price of $87.45, which implies an upside potential of 5.7% over Seattle Genetics’ closing price of $82.76 on October 3.

  • Analyzing Seattle Genetics’ Key Collaborations
    Market Realist12 days ago

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries. Adcetris was approved in Japan for treating frontline Hodgkin lymphoma. Seattle Genetics has a global collaboration with Takeda Pharmaceutical (TKPYY) to develop and commercialize Adcetris. While Seattle Genetics retains rights for the drug in the United States and Canada, Takeda has the rights for the drug in the rest of the world. Takeda pays Seattle Genetics a royalty.

  • Seattle Genetics: Impact of the Cascadian Acquisition
    Market Realist13 days ago

    Seattle Genetics: Impact of the Cascadian Acquisition

    Seattle Genetics’ (SGEN) net investment and other income increased from $2.91 million in the second quarter of 2017 to $106.56 million in the second quarter of 2018 due to net gains from its sale of Immunomedics common shares. As a result, the company posted a net income of $76.27 million in the second quarter—compared to a net loss of $56.36 million in the second quarter of 2017.

  • What’s Driving Seattle Genetics Stock in 2018?
    Market Realist13 days ago

    What’s Driving Seattle Genetics Stock in 2018?

    Seattle Genetics’ (SGEN) antibody-drug conjugate technology makes use of monoclonal antibodies’ targeting ability to deliver cell-killing agents to cancer cells. Adcetris, Seattle Genetics’ product on the market, is used to treat several types of lymphoma. The company also has a product pipeline targeted for solid tumors and blood-related cancers.

  • Ionis Pharmaceuticals’ Revenue Stream
    Market Realist13 days ago

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.

  • Why Analysts See a Massive Upside in Madrigal Stock
    Market Realist14 days ago

    Why Analysts See a Massive Upside in Madrigal Stock

    In October, of the nine analysts covering Madrigal Pharmaceuticals (MDGL), six have given its stock “buy” or higher ratings, and three have given it “hold” ratings. The mean rating for Madrigal stock is 2.11, and its target price is $322.86, implying an upside potential of 53.7% over its closing price of $210.08 on October 2. In comparison, peers Endocyte (ECYT) and Seattle Genetics (SGEN) have mean ratings of 1.25 and 2.15, respectively, and target prices of $23.33 and $86.09, respectively.

  • Business Wire14 days ago

    Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018

    Seattle Genetics, Inc. announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.

  • GlobeNewswire14 days ago

    Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Oct. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire16 days ago

    Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

    -ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of C

  • A Look at Sage Therapeutics’ NMDA Receptor Portfolio
    Market Realist26 days ago

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.

  • Business Wire26 days ago

    Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma

    -Approval Triggers Milestone Payment to Seattle Genetics of $10 Million-

  • Estimates and Recommendations for Shire on September 19
    Market Realist26 days ago

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • Why Seattle Genetics Inc (NASDAQ:SGEN) Is A Financially Healthy Company
    Simply Wall St.28 days ago

    Why Seattle Genetics Inc (NASDAQ:SGEN) Is A Financially Healthy Company

    Investors looking for stocks with high market liquidity and zero debt on the balance sheet should consider Seattle Genetics Inc (NASDAQ:SGEN). With a market valuation of US$12.09b, SGEN is aRead More...

  • GuruFocus.comlast month

    5 Health Care Stocks Gurus Are Buying

    Seattle Genetics tops the list

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realistlast month

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.

  • How’s Alkermes Positioned Financially in September?
    Market Realistlast month

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.

  • Business Wirelast month

    Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference

    Seattle Genetics, Inc. announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. EDT.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN